PE20090607A1 - Formulacion farmaceutica de dispersion liposomal en polvo seco - Google Patents

Formulacion farmaceutica de dispersion liposomal en polvo seco

Info

Publication number: PE20090607A1
Authority: PE; Peru
Prior art keywords: inhibitor; caspasa; dry powder; pharmaceutical formulation; antabidor4
Prior art date: 2007-08-24

Application number

PE2008001429A

Other languages

English (en)

Spanish (es)

Inventor

Fadi Eskandar

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-24

Filing date

2008-08-22

Publication date

2009-06-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40149638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090607(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-08-22 Application filed by Novartis Ag filed Critical Novartis Ag

2009-06-11 Publication of PE20090607A1 publication Critical patent/PE20090607A1/es

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000006185 dispersion Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 abstract 7
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 2
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 abstract 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
229920001202 Inulin Polymers 0.000 abstract 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 abstract 1
-1 SACROSE Chemical compound 0.000 abstract 1
239000008186 active pharmaceutical agent Substances 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
229940124748 beta 2 agonist Drugs 0.000 abstract 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
239000008121 dextrose Substances 0.000 abstract 1
229940088679 drug related substance Drugs 0.000 abstract 1
238000005538 encapsulation Methods 0.000 abstract 1
239000003623 enhancer Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000003862 glucocorticoid Substances 0.000 abstract 1
229940029339 inulin Drugs 0.000 abstract 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 1
239000008101 lactose Substances 0.000 abstract 1
150000002632 lipids Chemical class 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229940083466 soybean lecithin Drugs 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Dispersion Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PE2008001429A 2007-08-24 2008-08-22 Formulacion farmaceutica de dispersion liposomal en polvo seco PE20090607A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07114981		2007-08-24
EP07123163		2007-12-13

Publications (1)

Publication Number	Publication Date
PE20090607A1 true PE20090607A1 (es)	2009-06-11

Family

ID=40149638

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2008001429A PE20090607A1 (es)	2007-08-24	2008-08-22	Formulacion farmaceutica de dispersion liposomal en polvo seco

Country Status (5)

Country	Link
AR (1)	AR067997A1 (zh)
CL (1)	CL2008002479A1 (zh)
PE (1)	PE20090607A1 (zh)
TW (1)	TW200916126A (zh)
WO (1)	WO2009027337A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007264418B2 (en)	2006-06-30	2012-05-03	Iceutica Pty Ltd	Methods for the preparation of biologically active compounds in nanoparticulate form
MA33296B1 (fr)	2009-04-24	2012-05-02	Iceutica Pty Ltd	Nouvelle formulation d'indométhacine
WO2013009928A1 (en) *	2011-07-11	2013-01-17	Organic Medical Research	Cannabinoid formulations
US9682096B2 (en) *	2012-05-02	2017-06-20	Janssen R & D Ireland	Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections
WO2018160295A1 (en) *	2017-01-25	2018-09-07	Yiannios James John	Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same
US9526734B2 (en)	2014-06-09	2016-12-27	Iceutica Pty Ltd.	Formulation of meloxicam
US20190231783A1 (en) *	2018-02-01	2019-08-01	Corvus Pharmaceuticals, Inc.	Pharmaceutical formulations
MX2020007559A (es)	2018-02-01	2020-09-03	Corvus Pharmaceuticals Inc	Formulaciones farmaceuticas.
JP7632959B2 (ja) *	2018-11-13	2025-02-19	メルツファーマスーティカルズ，エルエルシー	吸入用の呼吸可能なポリヌクレオチド粉末製剤
US10729687B1 (en) *	2019-07-09	2020-08-04	Orexo Ab	Pharmaceutical composition for nasal delivery
CN114206906B (zh) *	2019-07-10	2024-02-20	香港大学	Peg化的合成kl4肽、其组合物和方法
CN114053226A (zh) *	2021-11-18	2022-02-18	上海欣峰制药有限公司	头孢米诺钠化合物的药物制剂及其制备方法
CN114209651A (zh) *	2021-11-18	2022-03-22	上海欣峰制药有限公司	头孢噻肟钠化合物的药物制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69629702T2 (de) *	1995-08-01	2004-06-17	Isis Pharmaceuticals, Inc., Carlsbad	Liposomale oligonukleotidzusammensetzungen
EP2660322A3 (en) *	2003-04-17	2013-11-13	Alnylam Pharmaceuticals Inc.	Modified iRNA agents
JPWO2005011632A1 (ja) *	2003-08-01	2006-09-14	独立行政法人産業技術総合研究所	糖鎖を有する標的指向性および腸管吸収制御性リポソームならびにそれを含む癌治療薬および診断薬
BRPI0509471A8 (pt) *	2004-05-05	2017-07-25	Atugen Ag	Lipídios, complexos de lipídio e uso dos mesmos
GB0418172D0 (en) *	2004-08-13	2004-09-15	Ic Vec Ltd	Vector
AU2005326371A1 (en) *	2005-01-28	2006-08-03	Kyowa Hakko Kirin Co., Ltd.	Composition for inhibiting expression of target gene
US20070172430A1 (en) *	2006-01-20	2007-07-26	Nastech Pharmaceutical Company Inc.	Dry powder compositions for rna influenza therapeutics
JP2009534342A (ja) *	2006-04-20	2009-09-24	サイレンス・セラピューティクス・アーゲー	血管内皮に特異的に送達するためのリポプレックス処方剤
GB0608838D0 (en) *	2006-05-04	2006-06-14	Novartis Ag	Organic compounds

2008
- 2008-08-21 AR ARP080103643A patent/AR067997A1/es unknown
- 2008-08-22 WO PCT/EP2008/061018 patent/WO2009027337A1/en not_active Ceased
- 2008-08-22 CL CL2008002479A patent/CL2008002479A1/es unknown
- 2008-08-22 PE PE2008001429A patent/PE20090607A1/es not_active Application Discontinuation
- 2008-08-22 TW TW097132233A patent/TW200916126A/zh unknown

Also Published As

Publication number	Publication date
WO2009027337A1 (en)	2009-03-05
CL2008002479A1 (es)	2009-05-08
TW200916126A (en)	2009-04-16
AR067997A1 (es)	2009-10-28

Publication	Publication Date	Title
PE20090607A1 (es)	2009-06-11	Formulacion farmaceutica de dispersion liposomal en polvo seco
ECSP10010224A (es)	2010-07-30	Formulaciones líquidas de hormona luteinizante (lh).
WO2009088414A3 (en)	2009-12-30	Oral pharmaceutical dosage forms
MX2015009772A (es)	2016-05-31	Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2008000442A1 (es)	2008-08-22	Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
CU20080052A7 (es)	2011-04-26	Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
AR051969A1 (es)	2007-02-21	Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central
CR20110110A (es)	2011-04-28	Composicion farmaceutica
SV2009003231A (es)	2009-11-09	Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o implementar la libido femenina
NO20081038L (no)	2008-04-23	Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering
AR070026A1 (es)	2010-03-10	Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
IL195269A0 (en)	2009-08-03	Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2010021607A3 (en)	2010-06-03	Pharmaceutical formulation
PH12014502331B1 (en)	2019-08-23	Orally available pharmaceutical formulation suitable for improved management of movement disorders
NI201100154A (es)	2012-01-24	Métodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento, prevención y manejo de la tuberculosis
WO2012085284A3 (en)	2012-09-20	High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
WO2008128191A3 (en)	2009-01-15	Oral cephalotaxine dosage forms
EP3453702A3 (en)	2019-05-15	Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof
WO2010029093A3 (en)	2010-09-16	Compositions for percutaneous administration
MX391191B (es)	2025-03-21	Composiciones de liberación extendida de onapristona y métodos.
ES2325291A1 (es)	2009-08-31	"uso de un extracto de silybum marianum"
UY29561A1 (es)	2006-12-29	Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR075866A1 (es)	2011-05-04	Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
TR201803451T4 (tr)	2019-07-22	Olmesartan formülasyonlari.
AR086252A1 (es)	2013-11-27	Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo

Legal Events

Date	Code	Title	Description
2010-03-17	FX	Voluntary withdrawal